Abstract
Objective The objective of this study is to determine how NF-κB-mediated inflammation disrupts thyroid specific genes/TFs/signaling pathways and the resultant increase in the risk of Follicular Thyroid Carcinoma.
Background Thyroid follicular carcinoma (FTC) is linked to chronic inflammation and NF-κB activation, which disrupts key thyroid-specific genes/transcription factors and signaling pathways. This dysregulation leads to impaired differentiation and increased proliferation, fostering oncogenesis. The interplay between NF-κB and thyroid components is critical for developing possible targeted therapies. This study aims to focus on these mechanisms, with the future potential of possibly improving diagnostic, prognostic, and therapeutic strategies for FTC.
Methods Databases, including PubMed, MEDLINE, Google Scholar, and open access/ subscription-based journals were searched for published articles without any date restrictions, to investigate how NF-κB-mediated inflammation disrupts thyroid specific genes/TFs/signaling pathways and the resultant increase in the risk of Follicular Thyroid Carcinoma. Based on the criteria mentioned in the methods section, studies were systematically reviewed to investigate the research question. This study adheres to relevant PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analyses).
Results NF-κB activation disrupts key thyroid transcription factors and signaling pathways, leading to increased risk of thyroid follicular carcinoma. Dysregulation of NKX2-1, PAX8, FOXE1, and HHEX impairs thyroid development and differentiation. NF-κB alters TSH signaling and disrupts RET/PTC, leading to aberrant cell proliferation. It further impacts the MAPK/ERK, PI3K/AKT, and Wnt/β- catenin pathways, driving oncogenic transformations. Additionally, NF-κB-induced changes in FGF, Shh, BMP, Notch, and TGF beta pathways exacerbate tumorigenesis by promoting abnormal cell growth and survival, collectively increasing follicular carcinoma risk.
Conclusion Chronic inflammation and NF-κB activation disrupt key transcription factors (NKX2-1, PAX8, FOXE1, HHEX) and signaling pathways (TSH, RET/PTC, MAPK/ERK, PI3K/AKT, Wnt/β-catenin, FGF, Shh, BMP, Notch, TGF-β) essential for thyroid development and function. This dysregulation leads to impaired differentiation, increased proliferation, and enhanced survival of thyroid follicular cells, fostering genomic instability and oncogenic transformation. These findings highlight the role of NF-κB in promoting follicular thyroid carcinoma (FTC) and points towards the need for targeted therapies to restore normal signaling and prevent malignancy in thyroid diseases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
I declare that there was not any source of funding for this research work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
All authors have read and approved the manuscript.
Abbreviations
- NF-κB
- Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells
- NKX2-1
- NK2 Homeobox 1
- PAX8
- Paired Box 8
- FOXE1
- Forkhead Box E1 (Thyroid Transcription Factor 2, TTF-2)
- HHEX
- Hematopoietically Expressed Homeobox
- TSH
- Thyroid Stimulating Hormone
- RET/PTC
- Rearranged during Transfection/Papillary Thyroid Carcinoma
- MAPK/ERK
- Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase
- PI3K/AKT
- Phosphoinositide 3-Kinase/Protein Kinase B
- Wnt/β-catenin
- Wnt Signaling Pathway/Beta-Catenin
- FGF
- Fibroblast Growth Factor
- Shh
- Sonic Hedgehog
- BMP
- Bone Morphogenetic Protein
- Notch
- Notch Signaling Pathway
- TGF beta
- Transforming Growth Factor Beta
